INM

InMed Pharmaceuticals Inc. (INM) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.8 (Moderate)

Negative ROIC and absent margin disclosure indicate weak current profitability, but the company’s cash conversion cycle is better than many peers, supporting liquidity.

A current and quick ratio above 3.0 suggests short-term balance-sheet resilience, which is stronger than typical small-cap peers with tighter working-capital buffers.

Very low debt-to-equity and modest net debt to EBITDA reduce refinancing pressure, leaving INM less levered than more indebted peers in the same universe.

Weaknesses

Score:

Negative ROIC shows capital is not yet earning its cost, leaving INM structurally behind profitable peers on value creation.

Missing operating and gross margin disclosure limits evidence of operating leverage, while peers with scale can convert revenue into earnings more efficiently.

The business appears small and financially conservative rather than advantaged, so its balance sheet strength does not offset weak return generation versus peers.

Opportunities

Score:

If management improves monetization of existing assets, INM can narrow the profitability gap versus peers because current liquidity provides room to execute.

A negative cash conversion cycle can support faster internal funding of growth than peers with working-capital drag, improving reinvestment capacity.

Low leverage leaves capacity to fund selective expansion or restructuring, which could strengthen competitive positioning if deployed into higher-return activities.

Threats

Score:

Persistent negative returns create a risk of continued underperformance versus peers, especially if capital remains tied to low-yield assets.

Peers with stronger margins and scale can outcompete INM on pricing and reinvestment, widening the structural gap over the next several years.

Limited disclosed growth and segment data increase uncertainty around durable demand drivers, making it harder to defend positioning against better-transparent competitors.

Overall Score

Score:

INM’s liquidity and low leverage provide some resilience, but negative returns and limited evidence of durable operating advantage leave it structurally weaker than peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on InMed Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →